Mycophenolate mofetil for myasthenia gravis
- 25 November 2003
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 61 (10), 1438-1440
- https://doi.org/10.1212/01.wnl.0000094122.88929.0b
Abstract
The authors report a retrospective analysis of the use of mycophenolate mofetil (MyM) in 85 patients with autoimmune myasthenia gravis. The Myasthenia Gravis Foundation of America (MGFA) postintervention status (PIS) was used to characterize the treatment response in each patient. Sixty-two patients (73%) achieved a PIS status indicating improvement. Quantitative strength testing performed on the majority of patients before and after treatment also improved. Side effects to MyM were observed in 27% of patients but required discontinuation in only 6%.Keywords
This publication has 12 references indexed in Scilit:
- Mycophenolate Mofetil for Myasthenia Gravis A Double‐Blind, Placebo‐Controlled Pilot StudyAnnals of the New York Academy of Sciences, 2003
- A Simple Manual Muscle Test for Myasthenia GravisAnnals of the New York Academy of Sciences, 2003
- Malignant Tumors After Renal TransplantationArtificial Organs, 2002
- Determination of Insulin-Like Growth Factor I in Children: Normal Values and Clinical UseHormone Research in Paediatrics, 2001
- Mycophenolate mofetil for myasthenia gravis: An open-label pilot studyNeurology, 2001
- Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseasesNeurology, 2001
- Myasthenia gravisNeurology, 2000
- Macroprolactinemia in Childhood and Adolescence: A Cause of Asymptomatic HyperprolactinemiaHormone Research in Paediatrics, 2000
- Azathioprine toxicity during long‐term immunosuppression of generalized myasthenia gravisNeurology, 1988
- Azathioprine toxicity in neuromuscular diseaseNeurology, 1986